← Back to headlines
Daré Bioscience Targets Ovaprene Phase III Milestone and Flora Sync LF5 Revenue
Daré Bioscience aims for Ovaprene Phase III to achieve 2,500 exposure cycles in 2026, with revenue from Flora Sync LF5 anticipated to commence in June.
15 May, 01:42 — 15 May, 01:42
Sources
Showing 1 of 1 sources
